FDA Clears Voyager's VY1706 IND, Paving Way for First Tau-Reducing Gene Therapy Trial in Alzheimer's
Summary
Voyager Therapeutics received FDA Investigational New Drug (IND) clearance for VY1706, its gene therapy for Alzheimer's disease. This allows the company to begin human clinical trials, with dosing expected in the second half of 2026. This follows positive 3-month GLP toxicology data for VY1706 presented on May 13th and an 8-K filed today confirming the clearance. VY1706 is positioned as the first gene therapy to reduce tau production in the brain for Alzheimer's, a novel approach in a disease with high unmet medical need. Advancing a lead candidate into human trials is a significant de-risking event and a major milestone for a biotech of this size. Initial patient dosing in the clinical trial is expected in H2 2026.
At the time of this announcement, VYGR was trading at $3.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $233.8M. The 52-week trading range was $2.65 to $5.55. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.